


Publikationen


Impakt-Punkte und H-Index

Originalarbeiten als Erst- oder Letztautor:	33
Originalarbeiten als Koautor oder Kollaborator:	37
Letter, Reviews, Case Reports:	21
Abstracts:	48
Impact-Faktor ¹ :	559,175
Zitierungen:	4420
i10-Index ² :	65
H-Index ³ :	36

Zitierung 2002-2022:



Geographische Verteilung der Zitierung:




¹ Summe der Zitierungen publizierter Artikel einer Zeitschrift im Verhältnis zur Anzahl der Artikel bezogen auf die letzten 2 Jahre


² Zahl der Publikationen mit mindestens 10 Zitierungen

³ Zahl der Publikationen mit mindestens ebenso vielen Zitierungen

Fokus Nordamerika und Europa:



Fokus Südostasien und Australien:



Publikationsliste

Originalarbeiten als Erst- oder Letztautor

		IF
1.	Chaganti S, Barlev A, Caillard S, Choquet S, Cwynarski K, Friedetzky A, González-Barca E, Sadetsky N, Schneeberger S, Thirumalai D, Zinzani PL, Trappe RU . <i>Expert consensus on the characteristics of patients with Epstein–Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLN) for whom standard-dose chemotherapy may be inappropriate: results from a modified Delphi study.</i> Adv Ther, 40(3):1267-1281, 2023	4.070
2.	Fotopolou C, Haidopoulos D, Trappe RU . <i>Peri-operative ovarian cancer guidelines: major intra-operative and post-operative bleeding and thromboembolic events.</i> Int J Gynecol Cancer, 32(12):1621-1622, 2022	4.661
3.	Zimmermann H, Koenecke C, Dreyling MH, Pott C, Dührsen U, Hahn D, Meidenbauer N, Hauser IA, Rummel MJ, Wolf D, Heuser M, Schmidt C, Schlattmann P, Ritgen M, Siebert R, Oschlies I, Anagnostopoulos I, Trappe RU . <i>Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLN-2 trial.</i> Leukemia, 36(10): 2468-2478,	12.883 (2021)

	2022	
4.	Zimmermann H, Nitsche M, Pott C, Reinke P, Babel N, Hermann RB, Hauser IA, Hahn D, Ritgen M, Pietschmann C, Klapper W, Anagnostopoulos I, Trappe RU . <i>Reduction of immunosuppression combined with whole brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLN registry.</i> Ann Hematol, 100(8): 2043-2050, 2021	4.030
5.	Borrows R, Scheer A, Cockwell P, Braun F, Anagnostopoulos I, Riess H, Zimmermann H, Trappe RU . <i>Serum free light chains adjusted for renal function are a potential biomarker for post-transplant lymphoproliferative disorders.</i> Ann Hematol, 98(3): 625-632, 2019	2.904
6.	Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Bachy E, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, Trappe RU . <i>Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder: A retrospective analysis based on the prospective, international, multicenter PTLN-1 trials.</i> Transplantation, 102(11): 1914-1923, 2018	4.593
7.	Zimmermann H, Denecke T, Dreyling MH, Franzius C, Reinke P, Subklewe M, Amthauer H, Kneba M, Riess H, Trappe RU . <i>End-of-treatment positron emission tomography after uniform first-line therapy of B cell posttransplant lymphoproliferative disorder identifies patients at low risk of relapse in the prospective German PTLN registry.</i> Transplantation, 102(5): 868-875, 2017	3.960
8.	Trappe RU , Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S. <i>Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder (PTLN) and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicentre phase II trial including 152 patients.</i> J Clin Oncol, 35:5, 536-543, 2017	26.360
9.	Trappe RU , Choquet S, Dierickx D, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Tarella C, Shpilberg O, Sender M, Salles G, Morschhauser F, Jaccard A, Lamy T, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Leithäuser M, Anagnostopoulos I, Raphael M, Riess H, Leblond V, Oertel S. <i>Thoracic organ transplant and high international prognostic index are associated with poor prognosis under sequential immunochemotherapy in CD20-positive post-transplant lymphoproliferative disorder (PTLN): clues from the prospective PTLN-1 trial for future stratification strategies.</i> American Journal of Transplantation, 15(4): 1091-100, 2015	5.683
10.	Fink SEK, Gandhi M, Nourse J, Keane C, Jöhrens K, Korfel A, Schmidt H, Neumann S, Tiede A, Jäger U, Dührsen U, Neuhaus R, Dreyling M, Borchert K, Südhoff T, Riess H, Anagnostopoulos I, Trappe RU . <i>A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLN identifies different patterns of EBV-association.</i> American Journal of Transplantation, 14(11): 2577-87, 2014	5.683
11.	Zimmermann H, Choquet S, Dierickx D, Dreyling MH, Moore J, Valentin A, Striefler JK, Riess H, and Trappe RU . <i>Early and late post-transplant lymphoproliferative disorder after lung transplantation – 34 cases from the European PTLN Network.</i>	3.535

	Transplantation, 96(3): e18-9, 2013	
12.	Zimmermann H, Moore J, Choquet S, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Tarella C, Leblond V, Riess H, Trappe RU . <i>The baseline differential blood count allows prognostic stratification in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial.</i> Leukemia, 27(10): 2102-5, 2013	9.379
13.	Evens AM, Choquet S, Smith SM, Kroll A, Leblond V, Roy R, Barton B, Schiff D, Habermann TM, Trappe R . <i>Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 72 Cases in the Modern Era.</i> American Journal of Transplantation, 13(6): 1512-22, 2013	6.192
14.	Zimmermann H, Reinke P, Neuhaus R, Lehmkühl H, Oertel S, Atta J, Planker M, Gärtner B, Lenze D, Anagnostopoulos I, Riess H, Trappe RU . <i>Burkitt post-transplant lymphoma in adult solid organ transplant recipients: Sequential immunochemotherapy with rituximab followed by CHOP or R-CHOP is safe and effective in an analysis of eight cases.</i> Cancer, 118(19): 4715-24, 2012	5.201
15.	Zimmermann H, Oeschles I, Fink S, Pott C, Neumayer HH, Lehmkühl H, Hauser IA, Dreyling M, Kneba M, Gärtner B, Anagnostopoulos I, Riess H, Klapper W, Trappe RU . <i>Plasmablastic post-transplant lymphoma: Cytogenetic aberrations and lack of EBV-association linked with poor outcome in the prospective German PTLD registry.</i> Transplantation, 93(5): 543-550, 2012	3.781
16.	Trappe R , Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkühl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S. <i>Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase II PTLD-1 trial.</i> The Lancet Oncology, 13(2): 196-206, 2012	25.117
17.	Pfiffer TEF, Seehofer D, Nicolaou A, Neuhaus R, Riess H, Neuhaus P, Trappe R . <i>Recurrent hepatocellular carcinoma in liver transplant recipients: incidence, risk factors and treatment options - a single center analysis on 139 patients in the sorafenib era.</i> Tumori, 97(4): 436-41, 2011	0.606
18.	Hinrichs C, Wendland S, Zimmermann H, Eurich D, Neuhaus R, Schlattmann P, Gärtner B, Anagnostopoulos I, Dörken B, Riess H, Reinke P, Trappe R . <i>IL-6 and TNF alpha plasma levels but not IL-10 plasma levels correlate with response to treatment in patients with PTLD: a longitudinal analysis from the German PTLD registry D 2006-2012.</i> Transpl Int, 224(9): 892-903, 2011	2.921
19.	Trappe R , Zimmermann H, Fink S, Reinke P, Dreyling M, Pascher A, Lehmkühl H, Gärtner B, Anagnostopoulos I, Riess H. <i>Plasmacytoma-like posttransplant lymphoproliferative disorder, a rare CD20-negative subtype of monomorphic B-cell PTLD, is associated with a favourable outcome in localized as well as in advanced disease - a prospective analysis of 8 cases from the German PTLD registry.</i> Haematologica, 96(7): 1067-71, 2011	6.424
20.	Trappe R , Hinrichs C, Appel U, Babel N, Reinke P, Neumayer HH, Budde K, Dreyling M, Dührsen U, Kliem V, Schüttrumpf S, Hauser IA, Mergenthaler HG, Schlattmann P, Dörken B, Anagnostopoulos I, Riess H. <i>Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft</i>	6.599

	<i>impairment after reduction of immunosuppression.</i> American Journal of Transplantation, 9(10): 2331-7, 2009	
21.	Trappe R , Choquet S, Reinke P, Dreyling M, Mergenthaler HG, Jäger U, Kebelmann-Betzing C, Jonas S, Lehmkuhl H, Anagnostopoulos I, LeBlond V, Hetzer R, Dörken B, Riess H, Oertel S. <i>The efficacy of single-agent rituximab in relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after first-line chemotherapy.</i> Transplantation, 84: 1708–1712, 2007	3.641
22.	Choquet S, Trappe R , LeBlond V, Jäger U, Riess H, Levy V, Raphael M, Davy F, Oertel S. The first two authors contributed equally and share first authorship. <i>Analysis of efficacy and safety of CHOP-21 as a second line treatment in post-transplant lymphoproliferative disorders (PTLD) unresponsive to a reduction in immunosuppression. A retrospective study on 26 cases.</i> Haematologica, 92:273-274, 2007	5.516
23.	Trappe R , Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Reinke P, Papp-Vary M, Dörken B, Oertel S. <i>Salvage chemotherapy for refractory and relapsed post-transplant lymphoproliferative disorder (PTLD) after treatment with single agent rituximab.</i> Transplantation, 93(7): 912-918, 2007	3.641
24.	Choquet S, Oertel S, LeBlond V, Riess H, Dörken B and Trappe R . <i>Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution.</i> Ann Hematol, 86(8): 599-607, 2007	2.342
25.	Oertel S, Trappe R , Papp-Vary M, Subklewe M, Zeidler K, Jonas S, Hummel M, Babel N, Reinke P, Dörken B, Riess H, Gärtner B. The first two authors contributed equally and share first authorship. <i>Epstein-Barr virus DNA in blood samples of adults with Post-Transplant Lymphoproliferative Disease does not correlate with clinical course.</i> Ann Hematol, 2006, 85(7):478-84, 2006	2.254
26.	Trappe R , Böhm D, Kohlhase J, Weise A, Liehr T, Essers G, Meins M, Zoll B, Bartelsl, Burfeind P. <i>A novel family specific translocation t(2;20)(p24.1;q13.1) associated with recurrent abortions: molecular characterization and segregation analysis in male meiosis.</i> Cytogenet Genom Res, 98, 1-8, 2002	1.993
27.	Trappe R , Schulze E, Rzymiski T, Fröde, S, Engel W. <i>The Caenorhabditis elegans ortholog of human PHF5a shows a muscle specific expression domain and is essential for C. elegans morphogenetic development.</i> Biol Biochem Res Comm, 297, 1049-1057, 2002	2.935
28.	Trappe R , Buddenberg P, Uedelhoven J, Gläser B, Buck A, Engel W, Burfeind P: <i>Identification and characterization of the murine zinc finger gene Znf131: predominant expression in testis, thymus and structures of the developing neuronal system.</i> Biol Biochem Res Comm, 296, 319-327, 2002	2.935
29.	Trappe R , Ahmed M, Gläser B, Vogel C, Tascou S, Burfeind P, Engel W: <i>Identification and characterization of a novel murine multigene family containing a PHD-finger-like motif.</i> Biol Biochem Res Comm, 293: 816-826, 2002	2.935
30.	Lacone F, Zoll B, Huppke P, Hanefeld F, W Pepinski, Trappe R . <i>MECP2 gene nucleotide changes and their pathogenicity in males: proceed with caution.</i> J Med Genet, 39:586-588,	7.774

	2002	
31.	Trappe R , Laccone F, Cobilanschi J, Meins M, Huppke P, Hanefeld F, Engel W. <i>MECP2 mutations in sporadic cases of Rett syndrome are of almost exclusively of paternal origin.</i> Am J Hum Genet, 68: 1093-1101, 2001	10.542
32.	Trappe R , Albig W, Doenecke D. <i>The expression of the human H2A-H2B histone genes pairs is regulated by multiple sequence elements in their joint promoters.</i> Biochem Biophys Acta, 1446: 341-351, 1999	2.590
33.	Albig W, Trappe R , Kardalidou E, Eick S, Doenecke D. The first two authors share first authorship. <i>The human H2A and H2B histone gene complement.</i> Biol Chem, 380: 7-18, 1999	3.356

Originalarbeiten als Koautor

		IF
34.	Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft HG, Arseniev L, Beier R, Beutel G, Cario G, Fröhlich B, Greil J, Hansmann L, Hasenkamp J, Höfs M, Hundsdoerfer P, Jost E, Kafa K, Kriege O, Kröger N, Mathas S, Meisel R, Nathrath M, Putkonen M, Ravens S, Reinhardt HC, Sala E, Sauer M, Schmitt C, Schroers R, Steckel NK, Trappe RU , Verbeek M, Wolff D, Blasczyk R, Eiz-Vesper B, Maecker-Kolhoff B. <i>Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors.</i> submitted, 2023	
35.	Walczak P, Choquet S, Dantal J, Boutboul D, Suarez F, Baron M, Morel V, Cluzeau T, Touati M, Elias M, Bachy E, Nicolas-Virelizier E, Houot R, Venton G, Jacquet C, Moles-Moreau MP, Jardin F, Durot E, Balegronne N, Ecotiere L, Guieze R, Kamar N, Ysebaert L, Couzi L, Gonzalez H, Roulin L, Ou K, Caillard S, Zimmermann H, Trappe RU , Roos-Weil D. <i>Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients.</i> Haematologica. doi: 10.3324/haematol.2022.282297, online ahead of print, 2023	13.200 (2022)
36.	Allen UD, Esquivel CO, L'Huillier AG, Bollard CM, Gross TG, Hayashi R, Höcker B, Maecker-Kolhoff B, Marks S, Mazariegos GV, Smets F, Trappe RU , Visner G, Chinnock RE, Comoli P, Danziger-Isakov L, Dulek DE, Dipchand A, Ferry JA, Martinez OM, Metes DM, Michaels M, Preiksaitis J, Squires J, Swerdlow S, Wilkinson JD, Dharnidharka V, Green M, Webber SA. <i>The IPTA Nashville Consensus Conference on Post-Transplant Lymphoproliferative Disorders after Solid Organ Transplantation in Children: IV – Consensus Guidelines for Management.</i> Pediatric Transplantation, accepted, 2023	1.438 (2021)
37.	Preiksaitis, J, Allen, U, Bollard, C.M, Dharnidharka, V, Dulek, DE, Green, M, Martinez, OM, Metes, DM8, Michaels, M, Smets, F, Chinnock, RE, Comoli, P, Danziger-Isakov, L, Dipchand, A, Esquivel, CO, Ferry, JA, Gross, TG, Hayashi, R, Höcker, B, L'Huillier, AG, Marks, S, Mazariegos, GV, Squires, J, Swerdlow, S, Trappe, RU , Visner, G, Webber, SA, Wilkinson, JD, Maecker-Kolhoff, B <i>The IPTA Nashville Consensus Conference on Post-Transplant Lymphoproliferative Disorders after Solid Organ Transplantation in Children: III - Consensus Guidelines for Epstein-Barr Virus Load and Other Biomarker Monitoring.</i> Pediatric Transplantation, accepted, 2023	1.438 (2021)
38.	Green M, Squires JE, Chinnock RE, Comoli P, Danziger-Isakov L, Dulek DE, Esquivel CO, Höcker B, L'Huillier AG, Mazariegos GV, Visner GA, Bollard CM,	1.438 (2021)

	Dipchand AI, Ferry JA, Gross TG, Hayashi R, Maecker-Kolhoff B, Marks S, Martinez OM, Metes DM, Michaels MG, Preiksaitis J, Smets F, Swerdlow SH, Trappe RU , Wilkinson JD, Allen U, Webber SA, Dharnidharka VR. <i>The IPTA Nashville consensus conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: II - consensus guidelines for prevention.</i> Pediatric Transplantation, e14350, online ahead of print, 2022	
39.	Sen A, Enriquez J, Rao M, Glass M, Balachandran Y, Syed S, Twist CJ, Weinberg K, Boyd SD, Bernstein D, Trickey A, Gratzinger D, Tan B, Lapasaran MG, Robien MA, Brown M, Armstrong B, Desai D, Mazariegos G, Chin C, Fishbein T, Venick RS, Tekin A, Zimmermann H, Trappe RU , Anagnostopoulos I, Esquivel CO, Martinez OM Krams SM. <i>Host microRNAs are Decreased in Pediatric Solid-Organ Transplant Recipients during EBV+ Post-transplant Lymphoproliferative Disorder</i> Frontiers in Immunology, 13: 994552, 2022	8.786
40.	Dreyling M, André M, Gökbuget N, Tilly H, Jerkeman M, Gribben J, Ferreri A, Morel P, Stilgenbauer S, Fox C, Maria Ribera J, Zweegman S, Aurer I, Bődör C, Burkhardt B, Buske C, Dollores Caballero M, Campo E, Chapuy B, Davies A, de Leval L, Doorduijn J, Federico M, Gaulard P, Gay F, Ghia P, Grønabæk K, Goldschmidt H, Kersten MJ, Kiesewetter B, Landman-Parker J, Le Gouill S, Lenz G, Leppä S, Lopez-Guillermo A, Macintyre E, Mantega MVM, Moreau P, Moreno C, Nadel B, Okosun J, Owen R, Pospisilova S, Pott C, Robak T, Spina M, Stamatopoulos K, Stary J, Tarte K, Tedeschi A, Thieblemont C, Trappe RU , Trümper LH, Salles G. <i>The EHA Research Roadmap: Malignant Lymphoid Diseases.</i> HemaSphere 6(6): e726, 2022	8.300
41.	Kutsch N, Pallasch C, Tausch E, Bohme V, Ritgen M, Liersch R, Wacker A, Jacobs G, Trappe RU , Dreger P, Fischer K, Fink AM, Stilgenbauer S, Zhai S, Jürgensmeier JM, Rajakumaraswamy N, Bhargava P, Hallek M, Eichhorst BF <i>Efficacy and safety of the combination of tirabrutinib and entospletinib with or without obinutuzumab in relapsed chronic lymphocytic leukemia</i> HemaSphere 6(4): e692, 2022	8.300
42.	Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Sauer T, Crysandt M, Rank A, Behringer D, Teichmann L, Görner M, Trappe RU , Röllig C, Krause S, Hanoun M, Hopfer O, Held G, Buske S, Fransecky L, Kayser S, Schliemann C, Schaefer-Eckart K, Al-Fareh Y, Schubert J, Geer T, Kaufmann M, Brecht A, Niemann D, Kieser M, Bornhäuser M, Platzbecker U, Serve H, Baldus CD, Müller-Tidow C, Schlenk RF. <i>Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.</i> Trials, 22(1): 765, 2021	2.049
43.	Fotopoulou C, Planchamp F, Aytulu T, Chiva L, Cina A, Ergönül Ö, Fagotti A, Haidopoulos D, Hasenburg A, Hughes C, Knapp P, Morice P, Schneider S, Sehouli J, Stamatakis E, Suria S, Taskiran C, Trappe RU , Campbell J <i>European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery</i> Int J Gynecol Cancer, 31(9): 1199-1206, 2021	3.437
44.	Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker F, Fuhrmann S, Leng C, Welslau M, Chemnitz J, Middeke JM, Weber T, Holtick U, Trappe R , Pfannes R, Liersch R, Spoer C, Fuxius S, Gebauer N, Caillé L, Geer T, Koenecke C, Keller U, Claus R, Mougiakakos D, Mayer S, Huettmann A, Pott C, Trummer A, Wulf G, Brunnberg U, Bullinger L, Hess G, Mueller-Tidow C, Glass B, Lenz G, Dreger P, Dietrich S <i>Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory</i>	5.846

	<i>large B-cell lymphomas</i> Blood Advances, 5(13): 2707-2716, 2021	
45.	Eyre TA, Caillard S, Finel H, Boumendil A, Kothari J, Zimmermann H, Trappe RU , De Wilde V, Tholouli E, Kanfer E, Broom A, Damaj G, Bargetzi M, Kozák T, Hilgendorf I, Crawley C, Kerre T, Trněný M, Bachy E, Robinson S, Montoto S <i>Autologous Stem Cell Transplantation for Post-Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A retrospective analysis from the Lymphoma Working Party of the EBMT</i> Bone Marrow Transplantation, 56(9): 2118-2124, 2021	5.483
46.	Gandhi MK, Hoang T, Law SC, Brosda S, O'Rourke K, Tobin JWD, Vari F, Murigneux V, Fink JL, Gunawardana J, Gould CM, Oey H, Bednarska K, Delecluse S, Trappe RU , de Long LM, Sabdia MB, Bhagat G, Hapgood G, Blyth E, Clancy LE, Wight J, Hawkes EA, Rimsza LM, Maguire A, Bojarczuk K, Chapuy B, Keane C <i>EBV-tissue positive primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.</i> Blood, 137(11):1468-1477, 2021	23.629
47.	Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R , Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance <i>Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.</i> The Lancet, 394(10216): 2271-2281, 2019	59.102
48.	Heidrich K, Thiede C, Schäfer-Eckart K, Schmitz N, Aulitzky WE, Krämer A, Rösler W, Hänel M, Einsele H, Baldus CD, Trappe RU , Stölzel F, Middeke JM, Röllig C, Taube F, Kramer M, Serve H, Berdel WE, Ehninger G, Bornhäuser M, Schetelig J; Study Alliance Leukemia (SAL) <i>Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.</i> Ann Oncol. 28(11): 2793-2798, 2017	11.855
49.	Brüwer G, Limperger V, Kenet G, Klostermeier UC, Shneyder M, Degenhardt F, Finckh U, Heller C, Holzhauer S, Trappe R , Kentouche K, Knoefler R, Kurnik K, Krümpel A, Lauten M, Manner D, Mesters R, Junker R, Nowak-Göttl U. <i>Impact of high risk thrombophilia status on recurrence among children and adults with VTE: An observational multicenter cohort study.</i> Blood Cells Mol Dis. 62: 24-31, 2016	1.882
50.	Jöhrens K, Trappe RU , Lenze D, Pfreundschuh M, Ziepert M, Hummel M, Anagnostopoulos I. <i>Age and cellular composition influence overall survival in a collective of non-immunocompromised patients with EBV-positive diffuse large B-cell lymphoma from a German lymphoma center.</i> Leuk Lymphoma, 27: 1-13, 2016	2.755
51.	Stuhlmann-Laeisz C, Borchert A, Quintanilla-Martinez L, Hoeller S, Tzankov A, Oshlies I, Kreuz M, Trappe R , Klapper W. <i>In Europe expression of EBNA2 is associated with poor survival in EBV-positive diffuse large B-cell lymphoma of the elderly.</i> Leuk Lymphoma, 57(1):39-44, 2016	2.755
52.	Rossignola J, Terrioua L, Robua D, Willekensa C, Hivert B, Pascala L, Guieze R, Trappe R , Baillet C, Huglo D, Morschhauser F.	5.683

	<i>Radioimmunotherapy (90 Y-ibritumomab tiuxetan) for post transplant lymphoproliferative disorders after prior exposure to Rituximab.</i> American Journal of Transplantation, 15(7):1976-81, 2015	
53.	Tiede A, Klamroth R, Scharf R, Trappe RU , Holstein K, Huth-Kühne A, Gottstein S, Geisen U, Schenk J, Scholz U, Schilling K, Neumeister P, Miesbach W, Manner D, Greil R, von Auer C, Krause M, Leimkühler K, Kalus U, Blumtritt M, Werwitzke S, Budde E, Koch A, Knöbl P. <i>Prognostic Parameters for Remission of and Survival in Acquired Hemophilia A (AHA).</i> Blood, 125(7): 1091-7, 2015	10.452
54.	Zimmermann H, Weiland T, Nourse JP, Gandhi M, Reinke P, Neuhaus R, Karbasiyan M, Gärtner B, Anagnostopoulos I, Riess H, Trappe RU , Oertel S. <i>Fcy-receptor IIIA polymorphism p.158 in CD20-positive posttransplant lymphoproliferative disorder (PTLD): data from prospective clinical trials provide evidence for competing rituximab effector mechanisms and ADCC-independent rituximab synergy with chemotherapy.</i> J Immunol Res, 2014: 264723, 2014	3.064
55.	Glott D, Chapman JR, Dharmidharka VR, Hanto DW, Castro MCR, Hirsch HH, Leblond V, Mehta AK, Moulin B, Pagliuca A, Pascual J, Rickinson AB, Russo FP, Trappe RU , Webster AC, Zuckermann AO, Gross TG. <i>The Seville Global Consensus Workshop for Progress in Post-Transplant Lymphoproliferative Disorders.</i> Transplantation, 94(8): 784-93, 2012	3.781
56.	Nourse JP, Crooks P, Keane C, Nguyen-Van D, Mujaj S, Ross N, Jones K, Vari F, Han E, Trappe R , Finke, S, Gandhi MK. <i>Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary EBV-positive lymphoma samples.</i> J Virol Methods, 2012, 184: 46-54, 2012	1.900
57.	Nguyen-Van D, Keane C, Han E, Jones K, Nourse JP, Vari F, Ross N, Crooks P, Ramuz O, Green M, Griffith L, Trappe R , Grigg A, Mollee P, Gandhi MK. <i>Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8+ T-cell epitopes.</i> Am J Blood Res, 1: 146-159, 2011	1.050
58.	Müller K, Schachtner T, Sattler A, Meier S, Friedrich P, Trydzenskaya H, Hinrichs C, Trappe R , Thiel A, Reinke P, Babel N. <i>BK-VP3 as a New Target of Cellular Immunity in BK Virus Infection.</i> Transplantation, 91(1): 100-7, 2011	4.004
59.	le Coutre P, Reinke P, Neuhaus R, Trappe R , Ringel F, Lalancette M, Hemmati PG, Dörken B, Daniel PT: <i>BCR-ABL positive cells and chronic myeloid leukaemia in immune suppressed organ transplant recipients.</i> Eur J Haematol, 84(1): 26-33, 2010	2.785
60.	Fotopoulou C, Karavas A, Trappe R , Chekerov R, Lichtenegger W, Sehouli J. <i>Prospective Value of Venous Thromboembolism in Recurrent Ovarian Cancer-Patients undergoing 2nd Line- Chemotherapy: An exploratory analysis of prospectively randomized topotecan-based studies of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO).</i> Thromb Res, 124(5): 531-5, 2009	2.038
61.	Fotopoulou C, duBois A, Karavas A, Trappe R , Aminossadati B, Schmal-feldt B, Pfisterer J, and Sehouli J. <i>Incidence of Venous Thromboembolism in Patients with Ovarian Cancer undergoing Platinum-Paclitaxel Containing First line-Chemotherapy: An exploratory analysis of the Arbeitsgemeinschaft Gynaekologische Onko-logie Ovarian Cancer Study Group (AGO-OVAR).</i>	17.157

	J Clin Oncol, 26(16), 2683-2689, 2008	
62.	Babel N, Vergopoulos A, Trappe RU , Oertel S, Hammer M, Karaivanov S, Schneider N, Riess H, Papp-Vary M, Neuhaus R, Gondek LP, Volk HD and Reinke P. <i>Evidence for genetic susceptibility towards development of post transplant lymphoproliferative disorders (PTLD) in solid organ recipients.</i> Transplantation, 84(3), 387-391, 2007	3.972
63.	Sebelin-Wulf K, Nguyen TD, Oertel S, Papp-Vary M, Trappe RU , Schulzki A, Pezzutto A, Riess H, Subklewe M. <i>Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.</i> Transpl Immunol, 17(3), 203-210, 2007	2.093
64.	Oertel S, Verschuuren E, Reinke P, Zeidler K, Papp-Vary M, Babel N, Trappe R , Jonas S, Hummel M, Anagnostopoulos I, Doerken B, Riess H. <i>Effect of anti-CD20 antibody Rituximab in patients with Post-Transplant Lymphoproliferative disease (PTLD).</i> American Journal of Transplantation, 5(12), 2901-2907, 2005	6.002
65.	Starke H, Nietzel A, Weise A, Heller A, Mrasek K, Belitz B, Kelbova C, Volleth M, Albrecht B, Mitulla B, Trappe R , Bartels I, Adolph S, Dufke A, Singer S, Stumm M, Wegner RD, Seidel J, Schmidt A, Kuechler A, Schreyer I, Claussen U, Von Eggeling F and Liehr T. <i>Small supernumerary marker chromosomes (SMCs): genotype phenotype correlation and classification.</i> Hum Genet, 14:51-67, 2003	4.022
66.	Tascou S, Kang TW, Trappe R , Engel W, Burfeind P. <i>Identification and characterization of NIF3L1 BP1, a novel cytoplasmatic interaction partner of NIF3L1.</i> Biol Biochem Res Comm, 309, 440-448, 2003	2.836
67.	Tascou S, Trappe R , Nayernia K, Jarry H, König F, Schulz-Schaeffer W, Saeger W, Meinhardt A, Schmidtke J, Engel W, Burfeind P. <i>TSPY-LTA transgenic mice develop endocrine tumors and tumors of the seminal vesicle.</i> Mol Cell Endocrinol, 200/1-2, 9-18, 2003	2.637
68.	Tascou S, Nayernia K, Meinhardt A, Schweyer S, Engel W, Trappe R , Burfeind P. <i>Targeted expression of SV40 large tumour antigen (TA_g) induces a transient enhancement of spermatocyte proliferation and apoptosis.</i> Mol Hum Reprod, 7(12):1123-1131, 2001	2.751

4.2.3. Originalarbeiten mit Listung als Kollaborator

		IF
69.	Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C and the iINNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. <i>Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.</i> N Engl J Med. 378(25): 2399-2410, 2018 Kollaboratoren (47): Advani RH, Arnulf B, Aurrant-Schleinitz T, Baldini L, Castillo JJ, Chen C, Cornell RF, Dreyling M, Dimopoulos MA, Dupuis J, Eradat H, Fernandez de Larrea C, Feugier P, Furman RR, Garcia Sanz R, Gorrochategui MG, Hatjiharissi E, Hebart H, Heffner L, Herbaux C, Hernandez Rivas JA, Hess G, Karlin L, Keating	72.406

	MM, Kyrtsolis MC, Launay V, Leblond V, Lee HP, Ma S, Mahe B, Matous J, McCarthy H, Oriol Rocafiguera A, Orsucci L, Palomba ML, Pfreundschuh M, Shustik C, Symeonidis A, Talaulikar D, Tam C, Tedeschi A, Tournilhac O, Trappe RU , Trotman J, Varettoni M, Venner CP, Vesole D, Zaja F.	
70.	Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ. <i>The European Hematology Association Roadmap for European Hematology Research: a consensus document.</i> Haematologica, 101(2): 115-208, 2016 Kollaboratoren (268): André M, Andre-Schmutz I, Bacigalupo A, Bochud PY, Boer Md, Bonini C, Camaschella C, Cant A, Cappellini MD, Cazzola M, Celso CL, Dimopoulos M, Douay L, Dzierzak E, Einsele H, Ferreri A, De Franceschi L, Gaulard P, Gottgens B, Greinacher A, Greinacher A, Gresele P, Gribben J, de Haan G, Hansen JB, Hochhaus A, Kadir R, Kaveri S, Kouskoff V, Kühne T, Kyrle P, Ljungman P, Maschmeyer G, Méndez-Ferrer S, Milsom M, Mummery C, Ossenkoppele G, Pecci A, Peyvandi F, Philippsen S, Reitsma P, Ribera JM, Risitano A, Rivella S, Ruf W, Schroeder T, Scully M, Socie G, Staal F, Stanworth S, Stauder R, Stilgenbauer S, Tamary H, Theilgaard-Mönch K, Thein SL, Tilly H, Trnemy M, Vainchenker W, Vannucchi AM, Viscoli C, Vrielink H, Zaaijer H, Zanella A, Zolla L, Zwaginga JJ, Martinez PA, van den Akker E, Allard S, Anagnou N, Andolfo I, Andrau JC, Angelucci E, Anstee D, Aurer I, Avet-Loiseau H, Aydinok Y, Bakchoul T, Balduini A, Balduini C, Barcellini W, Baruch D, Baruchel A, Bayry J, Bento C, van den Berg A, Bernardi R, Bianchi P, Bigas A, Biondi A, Bohonek M, Bonnet D, Borchmann P, Borregaard N, Brækkan S, van den Brink M, Brodin E, Bullinger L, Buske C, Butzeck B, Cammenga J, Campo E, Carbone A, Cervantes F, Cesaro S, Charbord P, Claas F, Cohen H, Conard J, Coppo P, Corrons JL, Costa Ld, Davi F, Delwel R, Dianzani I, Domanović D, Donnelly P, Drnovšek TD, Dreyling M, Du MQ, Dufour C, Durand C, Efremov D, Eleftheriou A, Elion J, Emonts M, Engelhardt M, Ezine S, Falkenburg F, Favier R, Federico M, Fenaux P, Fitzgibbon J, Flygare J, Foà R, Forrester L, Galacteros F, Garagiola I, Gardiner C, Garraud O, van Geet C, Geiger H, Geissler J, Germing U, Ghevaert C, Girelli D, Godeau B, Gökbuget N, Goldschmidt H, Goodeve A, Graf T, Graziadei G, Griesshammer M, Gruel Y, Guilhot F, von Gunten S, Gyssens I, Halter J, Harrison C, Hartevelde C, Hellström-Lindberg E, Hermine O, Higgs D, Hillmen P, Hirsch H, Hoskin P, Huls G, Inati A, Johnson P, Kattamis A, Kiefel V, Kleanthous M, Klump H, Krause D, Hovinga JK, Lacaud G, Lacroix-Desmazes S, Landman-Parker J, LeGouill S, Lenz G, von Lilienfeld-Toal M, von Lindern M, Lopez-Guillermo A, Lopriore E, Lozano M, MacIntyre E, Makris M, Makris M, Mannhalter C, Martens J, Mathas S, Matzdorff A, Medvinsky A, Menendez P, Migliaccio AR, Miharada K, Mikulska M, Minard V, Montalbán C, de Montalembert M, Montserrat E, Morange PE, Mountford J, Muckenthaler M, Müller-Tidow C, Mumford A, Nadel B, Navarro JT, Nemer We, Noizat-Pirenne F, O'Mahony B, Oldenburg J, Olsson M, Oostendorp R, Palumbo A, Passamonti F, Patient R, Peffault R, Pflumio F, Pierelli L, Piga A, Pollard D, Raaijmakers M, Radford J, Rambach R, Rao AK, Raslova H, Rebutta P, Rees D, Ribrag V, Rijneveld A, Rinalducci S, Robak T, Roberts I, Rodrigues C, Rosendaal F, Rosenwald A, Rule S, Russo R, Saglio G, Sanchez M, Scharf RE, Schlenke P, Semple J, Sierra J, So-Osman C, Soria JM, Stamatopoulos K, Stegmayr B, Stunnenberg H, Swinkels D, Barata JP, Taghon T, Taher A, Terpos E, Thachil J, Tissot JD, Touw I, Toyé A, Trappe R , Traverse-Glehen A, Unal S, Vaulont S, Viprakasit V, Vitolo U, van Wijk R, Wójtowicz A, Zeerleder S, Zieger B.	7.702

4.2.4. Letter, Reviews, Case Reports

		IF
71.	Choi M, Trappe R . <i>PTLD – rationale Prävention und Therapie</i> Nieren- und Hochdruckkrankheiten, Jahrgang 47, Nr. 5/2018: 294-302	0.090
72.	Trappe RU , Sinn M, Riess H.	0.552

	<i>Direct oral anticoagulants (DOAC) in tumor patients.</i> Deutsche Medizinische Wochenschrift, 141 (20): 1446-1450 2016	
73.	Kreher S, Ochsenreiter S, Trappe RU , Pabinger I, Bergmann F, Petrides PE, Koschmieder S, Matzdorff A, Tiede A, Griesshammer M, Riess H. <i>Management of venous thromboembolism in patients with myeloproliferative neoplasms: recommendations from the Haemostaseology Working Party of the German Society of Hematology and Oncology.</i> Ann Hematol, 93(12): 1953-63, 2014	2.634
74.	Nowak-Göttl U, Langer F, Limperger V, Mesters R, Trappe RU . <i>Bridging: Perioperatives Vorgehen bei dauerhafter oraler Antikoagulation oder Plättchenfunktionshemmung.</i> Deutsche Medizinische Wochenschrift, 139(24): 1301-1307, 2014	0.542
75.	Trappe RU and Zimmermann H. <i>EBV and PTLN: What to do?</i> Hematology Am Soc Hematol Educ Program, 95-102, 2013	2.857
76.	Trappe R , Budde U, Zimmermann H. <i>Haemorrhage due to proteolysis of coagulation factor XIII and hyper-fibrinolysis under vemurafenib treatment of metastatic melanoma.</i> Thrombosis Hemostasis, 23: 108(4), 2012	5.044
77.	Zimmermann H and Trappe R . <i>Therapeutic options in post-transplant lymphoproliferative diseases.</i> Therapeutic Advances in Hematology, 2(6): 393-407, 2011	2.110
78.	Cartron G, Trappe R , Solal-Céligny, Hallek M. <i>Interindividual variability of response to rituximab: from biological origins to individualized therapies.</i> Clin Cancer Res, 17(1):19-30, 2011	6.747
79.	Trappe R , Riess H, Anagnostopoulos I, Neuhaus R, Gärtner BC, Pohle H, Müller HP, Jonas S, Papp-Vary, Oertel S. <i>Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLN refractory to rituximab, chemotherapy and antiviral therapy alone.</i> Ann Hematol, 88(2): 167-72, 2009	2.919
80.	Trappe R , Pohl H, Forberger C, Schindler R and Reinke P. <i>Acute esophageal necrosis (black esophagus) in a CMV-negative renal transplant recipient: manifestation of "primary" CMV-infection.</i> Transpl Infect Dis, 9(1): 42-45, 2007	2.185
81.	Trappe R , Loew A, Thuss-Patience P, Doerken B, Riess H. <i>Successful treatment of primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab - monitoring of antiphospholipid and anti-GP antibodies: a case report.</i> Ann Hematol, 85:134-135, 2006	2.254
82.	Trappe R , Oertel SH, Riess H. <i>Zur Pathogenese, Klinik, Diagnostik und Therapie transplantationsassoziierter lymphoproliferativer Erkrankungen.</i> Deutsches Ärzteblatt, 103(48): A3259-3267, 2006	2.920
83.	Trappe R , Riess H. <i>Verbrauchskoagulopathie - disseminierte intravasale Gerinnung.</i> Intensivmedizin up2date, 2: 217-228, 2006	0.320
84.	Trappe R , Oertel SH, Riess H. <i>HIV-assoziierte Lymphome und Posttransplantationslymphome.</i> Der Onkologe, 7:641-650,	0.157

	2006	
85.	Roselfeld MT, Haverkamp W, Trappe R , Kujath P, Riess H. <i>Diagnostic and therapeutic management of patients receiving anti-thrombotic drugs: what to heed?</i> Deutsche Medizinische Wochenschrift, 131(17):982-6, 2006	0.584
86.	Trappe R and Riess H. <i>Pathophysiologische Grundsätze bei Sepsis, Basics in the pathophysiology of sepsis.</i> Hämostaseologie, 25, 175-182, 2005	1.602
87.	Trappe R , Riess H, Lippek F, Plotkin M, Hildebrandt B, Schumacher V, Royer-Pokora B, Zuber H, Mapara M, Oertel S, Doerken B. <i>Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult Wilms' tumor and a novel alteration in intron 1 of the WT1 gene.</i> J Pediatr Hematol Oncol, 26(12), 820-823, 2004	1.161
88.	Hildebrandt B, Wust P, Gellermann J, Nicolaou A, Trappe R , Felix R, Riess H, Rau B. <i>Treatment of Locally Recurrent Rectal Cancer with Special Focus on Regional Radiofrequency Hyperthermia.</i> Onkologie, 27, 506-511, 2004	1.283
89.	Hildebrandt B, Rau B, Gellermann J, Kerner T, Nicolaou A, Blohmer JU, Trappe RU , Riess H, Wust P. <i>Lokoregionäre Hyperthermie: Standards und neue Entwicklungen.</i> Wiener Medizinische Wochenschrift, 154, 7-8, 2004	0.240
90.	Brockmann K, Meins M, Taubert A, Trappe R , Grond M, Hanefeld F. <i>A Novel GFAP Mutation and Disseminated White Matter Lesions: Adult Alexander Disease.</i> European Neurology, 50(2): 100-105, 2003	1.042
91.	Meins M, Burfeind P, Motsch S, Trappe R , Schulz R, Langer S, Speicher M, Mühlendyck H, Bartels I, Zoll B. <i>Partial trisomy of chromosome 22 due to interstitial duplication of 22q11.2 in a child with typical cat eye syndrome.</i> J Med Genet, 40(5), E62, 2003	6.368

4.2.5. Publierte Abstracts

92.	Choquet S, Clark A, Renard C, Uttenthal B, Chaganti S, Trappe R , Comoli P, Duan X, Xing B, Wu C, Gamelin L, Terwey JH, Friedetzky A, Dierickx D. <i>Outcomes in patients with EBV+ PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe</i> ICML, accepted 2023	
93.	Choquet S, Clark A, Renard C, Uttenthal B, Chaganti S, Trappe R , Comoli P, Duan X, Xing B, Wu C, Gamelin L, Terwey JH, Friedetzky A, Dierickx D. <i>Treatment Outcomes and One-Year Survival in Patients with EBV+ PTLD Treated with Allogeneic EBV-specific CTL (tabelecleucel) under an Expanded Access Program in Europe</i> ASCO, accepted 2023	
94.	Trappe RU , Prockop S, Beitinjaneh A, Choquet S, Dahiya S, Dinavahi R, Farah R, Gamelin L, Ghobadi A, Mehta A, Reshef R, Satyanarayana G, Stiff P, Ye W, Mahadeo KM. <i>Tabelecleucel for EBV-Driven Post-Transplant Lymphoproliferative Disease Following Allogeneic Hematopoietic Cell or Solid Organ Transplant after Failure of</i>	

	<i>Rituximab ± Chemotherapy (ALLELE)</i> <i>Oncol Res Treat; 45 (suppl 2):52-53</i> 2022	
95.	Choquet S, Uttenthal B, Chaganti S, Comoli P, Trappe RU , Friedetzky A, Xing B, Li X, Polak TB, Gamelin L, Terwey JH, Dierickx D. <i>Demographics and Treatment Outcomes in Patients with EBV+ PTLD Treated with Off-the-Shelf EBV-specific CTL (Tabelecleucel) Under an Ongoing Expanded Access Program in Europe: First Analyses</i> <i>Oncol Res Treat; 45 (suppl 2):52</i> 2022	
96.	Dharnidharka V, Thirumalai D, Jaeger U, Zhao W, Dierickx D, Xun P, Minga P, Sawas A, Sadetsky N, Chauvet P, Sundaram E, Barlev A, Zimmermann H, Trappe RU . Clinical Outcomes of Solid Organ Transplant Patients With Epstein–Barr Virus-driven (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study <i>Oncol Res Treat; 45 (suppl 2):84</i> 2022	
97.	Choquet S, Uttenthal B, Chaganti S, Comoli P, Trappe R , Friedetzky A, Xing B, Li X, Polak TB, Gamelin L, Terwey J-H, Dierickx D. <i>Demographics and Treatment Outcomes in Patients with EBV+ PTLD Treated with Off-the-Shelf EBV-specific CTL (Tabelecleucel) Under an Ongoing Expanded Access Program in Europe: First Analyses</i> <i>Journal of Clinical Oncology, 40:16_suppl, 7530-7530,</i> 2022	
98.	Dharnidharka V, Thirumalai D, Jaeger U, Zhao W, Dierickx D, Xun P, Minga P, Sawas A, Sadetsky N, Chauvet P, Sundaram E, Barlev A, Zimmermann H, Trappe RU . <i>Clinical Outcomes Of Solid Organ Transplant (SOT) Patients With Epstein–Barr Virus-Driven (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study</i> <i>Am J Transplant, 22 (suppl 3),</i> 2022	
99.	Sen A, Enriquez J, Rao M, Glass M, Balanchandran Y, Syed S, Twist CJ, Weinberg K, Boyd SD, Bernstein D, Trickey A, Gratzinger D, Tan B, Lapasaran MG, Robien MA, Brown M, Armstrong B, Sever M, Desai D, Mazariegos G, Chin C, Fishbein T, Venick RS, Tekin A, Zimmermann H, Trappe RU , Esquivel CO, Martinez OM, Krams SM. <i>EBV+ PTLD tumor microRNAs are Detected in Circulating Extracellular Vesicles and are Decreased in Pediatric Transplant Recipients with EBV+PTLD</i> <i>Am J Transplant, 22 (suppl 3),</i> 2022	
100.	Zimmermann H, Koenecke C, Dreyling MH, Pott C, Dührsen U, Hahn D, Meidenbauer N, Hauser IA, Rummel MJ, Wolf D, Heuser M, Schmidt C, Schlattmann P, Ritgen M, Siebert R, Oschlies I, Anagnostopoulos I, Trappe RU . <i>Modified Risk-Stratified Sequential Treatment in B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) after Solid Organ Transplantation (SOT): The Prospective Multicenter Phase II PTLD-2 Trial.</i> <i>Blood 138 (Suppl.1): 3555,</i> 2021	
101.	Dharnidharka V, Thirumalai D, Jaeger U, Zhao W, Dierickx D, Xun P, Minga P, Sawas A, Sadetsky N, Chauvet P, Sundaram E, Barlev A, Zimmermann H, Trappe RU . <i>Clinical Outcomes of Solid Organ Transplant Patients with Epstein-Barr Virus-Driven (EBV+) Post-Transplant Lymphoproliferative Disorder (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study</i> <i>Blood, 138 (Suppl. 1): 2528,</i> 2021	
102.	Liebers N, Duell J, Nörenberg D, Kaebisch E, Kerkhoff A, Acker F, Fuhrmann S, Leng C, Welslau M, Chemnitz J, Middeke JM, Weber T, Trappe RU , Pfannes R, Liersch R, Spoer C, Gebauer N, Fuxius S, Caillé L, Pott C, Koenecke C, Holtick U, Geer T, Keller U, Claus R, Mougiakakos D, Mayer S, Hüttmann A, Trummer A, Wulf	

	G, Brunnberg U, Bullinger L, Hess G, Mueller-Tidow C, Glass B, Lenz G, Dreger P, Dietrich S. <i>Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)</i> Blood 136 (Suppl. 1): 11–13, 2020	
103.	Zimmermann H, Könecke C, Dreyling MH, Pott C, Dührsen U, Meidenbauer N, Hahn D, Heuser M, Schmidt C, Ritgen M, Siebert R, Klapper W, Anagnostopoulos I, Trappe RU for the German PTLD Study Group and German Lymphoma Alliance. <i>Treatment stratification in B-cell PTLD after solid organ transplantation (SOT) by international prognostic index (IPI) and response to rituximab: Interim results from the PTLD-2 trial</i> J Clin Oncol 38: Abstract 8045, 2020	
104.	Zimmermann H, Choquet S, Herbaux C, Chauvet P, Ren J, Zhang Y, Thirumalai D, Xu H, Barlev A, Reitan J, Trappe RU . <i>Adverse events and clinical burden associated with chemotherapy in patients with relapsed or refractory EBV+PTLD following SOT: a retrospective chart review study from Germany and France</i> EHA Library, EP1267 2020	
105.	Eyre TA, Caillard S, Finel H, Boumendil A, Kothari J, Zimmermann H, Trappe RU , De Wilde V, Tholouli E, Kanfer E, Broom A, Damaj G, Bargetzi M, Kozák T, Hilgendorf I, Crawley C, Kerre T, Trněný M, Salles G, Robinson S, Montoto S. <i>Autologous stem cell transplantation in post-transplant lymphoproliferative disorders: a retrospective analysis from the lymphoma working party of the EBMT</i> EHA Library, EP1417 2020	
106.	Zimmermann H, Könecke C, Dreyling MH, Pott C, Dührsen U, Meidenbauer N, Hahn D, Heuser M, Schmidt C, Ritgen M, Siebert R, Klapper W, Anagnostopoulos I, Trappe RU for the German PTLD Study Group and German Lymphoma Alliance. <i>Treatment stratification in B-cell PTLD after solid organ transplantation by transplanted organ, international prognostic index (IPI) and response to rituximab: Interim results from the PTLD-2 trial</i> EHA Library, EP1214 2020	
107.	Gandhi MK, Hoang T, Tobin JW, Law SC, Talaulikar D, Jain S, Vari F, Murigneux V, Fink L, Gunawardana J, Gould C, Oey H, Delecluse S, Trappe RU , Merida de Long L, Sabdia MB, Bhagat G, Hapgood G, Blyth E, Clancy L, Casey J, Wight J, Hawkes E, Keane C. <i>The tumour microenvironment and genetic profile of EBV+ CNS lymphomas is amenable to combination 3rd Party EBV-specific CTL and ibrutinib</i> New Directions in Leukemia Research, 2020	
108.	Kutsch N, Pallasch C, Tausch E, Boehme V, Ritgen M, Liersch R, Wacker A, Jacobs G, Trappe RU , Dreger P, Stilgenbauer S, Zhang D, Jürgensmeier JM, Bhargava P, Hallek M, Eichhorst B. <i>A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia</i> Blood, 134 (Suppl. 1): 4297, 2019	
109.	Zimmermann H, Xu H, Barlev A, Zhang Y, Thirumalai D, Watson C, Trappe R . <i>Burden of hospitalizations due to Epstein-Barr Virus associated (EBV+) Post-Transplant Lymphoproliferative disorder (PTLD) in patients who failed first line rituximab or rituximab plus chemotherapy: A Retrospective Chart Review Study of German PTLD Registry</i> Blood, 134 (Suppl. 1): 65, 2019	
110.	Gandhi MK, Hoang T, Tobin J, Law S, Talaulikar D, Jain S, Vari F, Murigneux V,	

	Fink L, Gunawardana J, Gould C, Oey H, Fink S, Trappe R , Merida de Long L, Bilalsabdia M, Blyth E, Clancy L, Casey L, Wight J, Hawkes E, Keane C. <i>EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3rd party ebv-specific CTL and ibrutinib therapy</i> Hematological Oncology, 37 (Suppl. 2): 130-132, 2019	
111.	Zimmermann H, Xu H, Barlev A, Feng A, Li X, Navarro W, Trappe RU . <i>Clinical outcomes of solid organ transplant patients with EBV+ PTLD who fail first-line rituximab or rituximab plus chemotherapy: an analysis of the German PTLD registry</i> EHA Library, 266518, PF719, 2019	
112.	Balachandran Y, Zimmermann H, Esquivel C, Krams S, Trappe RU , Martinez OM. <i>Elucidation of the miRNome in EBV-positive and EBV-negative PTLD</i> Transplantation, 102, s96, 2018	
113.	McPherson M, Balachandran Y, Boyd S, Zimmermann H, Trappe RU , Esquivel C, Krams S, Martinez OM. <i>Genomic status of the Epstein Barr Virus and Virus-associated PI3K/Akt/mTOR pathway dysregulation in post-transplant lymphoproliferative disorder</i> Transplantation, 102, s95, 2018	
114.	Gandhi MK, Keane C, Tobin JWD, Talaulikar D, Jain S, Vari F, Kruze L, Murigneux V, Fink L, Gunawardana J, Gould C, Oey H, Fink S, Trappe RU , Mathews M, Francis S, Hoang T. <i>The Impact of EBV upon the Tumor Microenvironment and Mutational Profile of Primary CNS Lymphoma in PTLD</i> Blood, 30: 2731, 2017	
115.	Heidrich K, Thiede C, Schäfer-Eckart K, Schmitz N, Aulitzky WE, Krämer A, Rösler W, Hänel M, Einsele H, Baldus CD, Trappe RU , Stölzel F, Middeke JM, Röllig C, Kramer M, Serve H, Berdel WE, Ehninger G, Bornhäuser M, Schetelig J. <i>Allogeneic Stem Cell Transplantation Improves Survival in Patients with FLT3-ITD-Negative and NPM1-Wild Type Intermediate Risk (ELN) Acute Myeloid Leukemia</i> Blood, 128: 3493, 2016	
116.	Trappe, RU , Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles GA, Kliem V, Tarella C, Van Den Neste EW, Hauser IA, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S. <i>Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients</i> Blood, 126: 816, 2015	
117.	Zimmerman H, Schaffert S, Lin D, Maecker H, Krams S, Esquivel C, Trappe R , Martinez O. <i>High Dimensional Phenotypic and Functional Analysis of The Immune Response During Post-Transplant Lymphoproliferative Disorder Using Mass Cytometry</i> Transplantation, 98, B793, 2014	
118.	Trappe RU , Cooke C, Heatley R, Johnson KI, Wiesner C. <i>PRM142 Use of body surface area as a determinant of dose in cancer studies</i> Value in Health, 15 (7), A486, 2012	
119.	Trappe RU , Dierickx D, Reinke P, Neuhaus R, Morschhauser F, Zaucha JM, Mollee P, Zimmermann H, Dreyling MH, Dührsen U, Verhoef G, Lehmkuhl H, Subklewe M, Hüttmann A, Tousseyn T, Torella C, Leblond V, Anagnostopoulos I, Riess H, Choquet S. <i>Risk-stratified sequential treatment (RSST) with rituximab and R-CHOP in adult CD20-positive post-transplant lymphoproliferative disorder (PTLD)</i>	

	J Clin Oncol, Abstract 8030, 2012	
120.	Evens AM, Choquet S, Smith SM, Kroll A, Leblond V, Roy R, Barton B, Schiff D, Habermann TM, Trappe R. <i>Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era</i> Blood, Abstract 879 2011	
121.	Trappe R , Oertel S, LeBlond V, Mollee P, Monica S, Reinke P, Neuhaus R, Lehmkühl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Anagnostopoulos I, Raphael M, Riess H, Choquet S. <i>Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLTD-1 Trial</i> Blood, 2011, Abstract 878 2011	
122.	Evens AM, Choquet S, Smith SM, Leblond V, Roy R, Habermann TM, Trappe R. <i>Primary Central Nervous System (CNS) Post-Transplant Lymphoproliferation (PTLD): An International Report of 52 Cases in the Rituximab Era</i> Ann Oncol, 22 (4): iv99, Abstract 054 2011	
123.	Hinrichs C, Wendland S, Eurich D, Neuhaus R, Schlattmann P, Gärtner B, Anagnostopoulos I, Riess H, Reinke P, Trappe RU. <i>IL-6 and TNF alpha plasma levels but not IL-10 plasma levels correlate with response to treatment in patients with PTLTD: a longitudinal analysis from the German PTLTD registry D 2006-2012</i> Transplantation, 90: 258, Abstract 1567 2010	
124.	Trappe RU , Choquet S, Leblond V, Dierickx D, Mollee P, Zaucha JM, Sender M, Ekman T, Reinke P, Neuhaus R, Lehmkühl H, Dreyling MH, Dührsen U, Salles G, Morschhauser F, Jaccard A, Lamy T, Anagnostopoulos I, Raphael M, Riess H. <i>Risk Stratified Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLTD - Defining a New Standard of Care: Results From a Prospective International Multicenter Trial</i> Transplantation, 2010, 90:257, Abstract 1322 2010	
125.	Pfiffer TEF, Seehofer D, Nicolaou A, Neuhaus R, Neuhaus P, Riess H, Trappe RU. <i>Incidence, risk factors and treatment options of recurrent hepatocellular carcinoma in liver transplant recipients: a single center analysis on 139 patients in the sorafenib era</i> J Clin Oncol, Abstract 4088 2010	
126.	Trappe R , Choquet S, Oertel S, LeBlond V, Dierickx D, Mollee P, Monica S, Ekman T, Zaucha JM, Reinke P, Neuhaus R, Lehmkühl H, Dreyling M, Dührsen U, Salles G, Morschhauser F, Jaccard A, Lamy T, Anagnostopoulos I, Raphael M, Dörken B, Riess H. <i>Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLTD - Moving forward to a first Standard of Care</i> Blood, Abstract 100, 2009	
127.	Appel U, Hinrichs C, Reinke P, Babel N, Neumayer HH, Dreyling M, Dührsen U, Kliem V, Schüttrumpf S, Hauser I, Mergenthaler HG, Anagnostopoulos I, Riess H, Trappe R. <i>Reduction of immunosuppression and subsequent rituximab monoherapy or CHOP-based chemotherapy +/- rituximab as a treatment for PTLTD does no impair the renal graft function: a matched pair control analysis in 55 renal transplant recipients with PTLTD and 1075 renal transplant controls</i> Blood, 112, Abstract 3614, 2008	
128.	Choquet S, Oertel S, Anagnostopoulos I, Riess H, Leblond V, Trappe R: <i>Results of the largest study on post-transplant-lymphoproliferations (PTLDs) of the central</i>	

	<i>nervous system (CNS) in the rituximab era: a surprising overrepresentation of kidney transplantations, key importance of methotrexate (Mtx), cytarabine (AraC) and radiotherapy (RX) for long term survival and low impact of rituximab (R)</i> Blood, 112, Abstract 3613, 2008	
129.	Le Coutre P, Reinke P, Neuhaus R, Trappe R , Ringel F, Hemmati P, Dörken B and Daniel P. <i>Evolution of BCR-ABL positive cells in peripheral blood leukocytes of immune suppressed post-transplant kidney or liver recipients</i> Blood, 112: Abstract 3191 2008	
130.	Trappe R , Choquet S, Oertel S, LeBlond V, Ekman T, Monica S, Mollee P, Reinke P, Lehmkühl H, Hummel M, Jonas S, Neuhaus R, Salles G, Morschhauser F, Jaccard A, Dierickx D, Lamy T, Anagnostopoulos I, Raphael M, Riess H. <i>Sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD – will risk stratified treatment become the new standard in therapy?</i> Transplantation, 86 (Suppl. 2S), 103-104, Abstract 292, 2008	
131.	Trappe R , Choquet S, Oertel S, LeBlond V, Ekman T, Monica S, Mollee P, Reinke P, Lehmkühl H, Hummel M, Jonas S, Neuhaus R, Salles G, Morschhauser F, Jaccard A, Dierickx D, Anagnostopoulos I, Raphael M, Riess H. <i>Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD: A New Standard in Therapy?</i> Blood, 110(11), Abstract 390, 2007	
132.	Trappe R , Choquet S, Oertel S, LeBlond V, Ekman T, Sender M, Mollee P, Reinke P, Lehmkühl H, Hummel M, Jonas S, Neuhaus R, Salles G, Morschhauser F, Jaccard A, Anagnostopoulos I, Raphael M, Riess H. <i>Efficacy and safety of sequential treatment with Rituximab and CHOP chemotherapy in B-cell PTLD: results of a prospective international phase II study</i> Am J Transplant (Suppl.), 317, Abstract 648, 2007	
133.	Trappe R , Riess H. <i>Rituximab in the treatment of alloimmune factor VIII antibodies in an adult with mild haemophilia</i> Haemophilia, 12 (Suppl. 2), 14 PO 429, 2006	
134.	Oertel SHK, Verschuuren E, Reinke P, Zeidler K, Papp-Váry M, Babel N, Trappe RU , Jonas S, Hummel M, Anagnostopoulos I, Dörken B, Riess HB. <i>Effect of Anti-CD 20 Antibody Rituximab in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD)</i> Am J Transplant, 5 (12), 2005	
135.	Trappe R , Oertel SH, Choquet S, LeBlond V, Papp-Vary M, and Riess H. <i>Sequential Treatment With The anti-CD 20 Antibody Rituximab And CHOP+GCSF Chemotherapy In Patients With Post-transplant Lympho-proliferative Disorder (PTLD): First Results Of A Multicenter Phase II Study</i> Blood, 106(11), Abstract 274a, 2005	
136.	Meins M, Trappe R , Motsch S, Schulz R, Langer S, Speicher M, Mühlendyck H, Bartels I, Burfeind P, Zoll B. <i>Partial trisomy of chromosome 22 due to interstitial duplication of 22q11.2 in a child with typical cat eye syndrome</i> medgen, 14, 284, 2002	
137.	Trappe R , Kohlhase J, Böhm D, Weise A, Leibr T, Essers G, Meins M, Zoll B, Bartels I, Burfeind P. <i>Partial monosomy 20q13.1-qter and 2p24.1-pter is associated with multiple abortions: molecular characterization and segregation analysis in a family bearing a t(2;20) translocation</i> medgen, 14, Abstract 283, 2002	

138.	Trappe R , Cobilanschi J, Meins M, Huppke P, Hahnefeld F, Engel W, Laccone F. <i>MECP2 mutations in Sporadic Cases of Rett Syndrome are exclusively of paternal origin</i> Eur J Hum Genet, 9 (1), 88, 2001	
139.	Trappe R , Albig W, Doenecke D. <i>Organization and Expression of the Human H2A/H2B Histone Gene complement.</i> Biol Chem, 380 Special Supplement, 202, 1999	